The COSMYC Trial (COmbined Suppression of MYC)

This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigators also want to determine if dosing first with the combination of testosterone and ZEN-3694 may cause enzalutamide and ZEN-3694 to work more effectively.

Trial Details

NCT ID

NCT06922318

Phase

PHASE2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Status

RECRUITING

Cancer Type

Castration-Resistant (CRPC) Prostate Cancer

Interventions

ZEN-3694
Testosterone cypionate
Enzalutamide
Luteinizing hormone-releasing hormone (LHRH) analogue

Locations (sample)

Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

Eastern Cooperative Oncology Group (ECOG) Performance status ≤2.
Age ≥18 years.
Histologically-confirmed adenocarcinoma of the prostate.
Treated with continuous androgen ablative therapy (either surgical castration or LHRH agonist/antagonist).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Castration-Resistant (CRPC) Prostate Cancer Trials on Trialify →